retatrutide release date Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. Adam Tirzepatide vs. Retatrutide: Key Differences

However, newer medications target multiple metabolic hormones: GLP-1 drugs (single-hormone): semaglutide medications like Wegovy and Ozempic Dual-agonist drugs: tirzepatide medications like Mounjaro and Zepbound (target GLP-1 and GIP receptors) Triple-agonist drugs: retatrutide (targets GLP-1, GIP and glucagon receptors) Researchers believe stimulating multiple hormone pathways may produce stronger effects on appetite, metabolism and energy expenditure

Your provider will guide you in proper injection techniques and site rotation

GLP-1 drugs may also have a direct effect on your hair and trigger it to stop growing

Large observational studies from electronic health records show that people prescribed GLP-1 agonists for diabetes or obesity are associated with fewer alcohol-related hospitalizations compared to those on other medications

503A pharmacies - which compound medications for individual patients based on specific prescriptions from licensed providers - operate under a different framework

Small-molecule GLP-1RA litigation over the coming decade will likely generate more numerous, more independently contested patent challenges than peptide GLP-1RA litigation has